九典制药(300705.SZ)发布前三季度业绩，归母净利润4.06亿元，下降9.64%

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) reported a revenue of 2.268 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 5.69% [1] - The net profit attributable to shareholders decreased by 9.64% to 406 million yuan [1] - The net profit after deducting non-recurring gains and losses was 391 million yuan, down 6.47% year-on-year [1] - Basic earnings per share stood at 0.82 yuan [1] Financial Performance - Revenue for the first three quarters: 2.268 billion yuan, up 5.69% year-on-year [1] - Net profit attributable to shareholders: 406 million yuan, down 9.64% year-on-year [1] - Net profit after non-recurring items: 391 million yuan, down 6.47% year-on-year [1] - Basic earnings per share: 0.82 yuan [1]